India's Typhoid Economic Burden
Analysis based on 6 articles · First reported Mar 25, 2026 · Last updated Mar 27, 2026
The study highlights a significant economic burden on India due to antibiotic-resistant typhoid, which could lead to increased government spending on healthcare and vaccination programs. This may create opportunities for pharmaceutical companies involved in vaccine development and antibiotic resistance control.
A study published in The Lancet Regional Health Southeast Asia revealed that antibiotic-resistant typhoid infections accounted for at least 87% of India's disease-related economic burden in 2023, totaling ₹12,300 crore. Children under 10 bore over half of these costs, and households covered 91% of expenses, with 70,000 families facing catastrophic health expenditure. High-burden states like India — Maharashtra, India — Uttar Pradesh, India — Andhra Pradesh (including India — Telangana), India — Tamil Nadu, and India — West Bengal accounted for 51% of national costs. The study, conducted by researchers from institutions including London School of Hygiene and Tropical Medicine and Christian Medical College Vellore, emphasizes the role of fluoroquinolone resistance in driving these costs. The findings provide evidence to support the introduction of the typhoid conjugate vaccine in India's national immunisation schedule and enhance antibiotic resistance control.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard